In October, we saw the GL Capital-lead consortium takeover of SciClone Pharmaceutical, a specialty small-molecule company, for about USD$600 million. Chinese, Indian and Australian biopharmas also had a busy year. Fosun Group (China) acquired a 74% stake in Hyderabad-based Gland Pharma ...
Read more: Healthcare M&A outlook bright for 2018: Analysts